arrow
L

Lars Erik Bryld

Zealand University Hospital
H指数:18
被引数:1,865

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study

从阿达木单抗原创者强制性非医疗转换为银屑病后,生物仿制药SB5与GP2017的真实世界药物存活率: 一项全国性队列研究

2025-01-010
OAAI
Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment- a Nationwide Cohort Study

阿达木单抗、苏金单抗和乌司他单抗治疗银屑病的药物生存期,由治疗前3年剂量递增或停药决定 -- 一项全国性队列研究

2023-11-0112
OAAI